Sponsored company news and issuer-paid coverage. Wall Street Wire articles are paid promotional content; see each article’s disclaimer.
Alpha Tau Medical (NASDAQ: DRTS) announced on October 22 that it has signed a memorandum of understanding with Samsung Medical Center in Seoul to explore a pancreatic cancer trial. The hospital ranked fifth worldwide in oncology in Newsweek’s 2027 specialized hospital rankings, according to the announcement. A Korean study
PJM Interconnection’s 2028/2029 capacity auction cleared at the FERC-approved cap of $325 per MW-day on July 14, 2026 and still procured 6,831 megawatts less than its reliability requirement, an explicit signal that firm dispatchable power is now scarce inside the grid region running through the
Beyond Oil is selling a patented technology that helps commercial kitchens keep frying oil cleaner and usable longer – already proven with paying customers abroad, and now beginning to gain traction in the vast U.S. foodservice market where successful execution could ‘materially change the company’s revenue scale’ according to
The Bottom Line: The U.S. has just 7 months to replace Chinese rare earth magnets in defense systems – and EMAT may be the only Western company already producing them at commercial scale. With Pentagon-aligned leadership, operational capacity in Korea, and a massive U.S. buildout underway, EMAT is
SalesCloser Technologies begins trading with over C$2M in annual recurring revenue and 6x growth
Neurocrine Biosciences’ lightning-fast $2.9 billion takeover of Soleno Therapeutics (NASDAQ: SLNO) isn’t your typical biotech M&A deal. It’s a full-blown repricing event that just lit a fire under an entirely new corner of the obesity market. The prize? Prader-Willi syndrome (PWS) – a
TL;DR: Alpha Tau (NASDAQ: DRTS) is emerging as a differentiated player in one of oncology’s fastest-growing areas – targeted radiation – but with a fundamentally different approach. Instead of competing in crowded systemic radiopharmaceuticals, its Alpha DaRT technology delivers highly potent radiation directly inside tumors, with early data showing
Duke Robotics Corp*. (OTCQB: DUKRD) (ISIN: US9034482078) hat heute eine Nachricht veröffentlicht, die das Bild des 18-Millionen-Dollar-Unternehmens grundlegend verändern könnte: einen Millionen-Auftrag von der Israel Electric Corporation für drohnenbasierte Wartungs- und Reinigungsdienste an elektrischer Infrastruktur, der das bisherige Geschäftsvolumen im Energiesektor verdoppelt. Und dies könnte erst
Battlefield-tested technology, a utility grid contract, and an AI product launch, all as a unprecedented war reshapes global defense priorities. Duke Robotics (OTCQB: DUKRD) is checking a lot of boxes before most investors are paying attention.
TL;DR: Alpha Tau Medical Ltd. (NASDAQ: DRTS) is developing Alpha DaRT, a localized alpha-radiation therapy for solid tumors. Since late 2023, pharmaceutical giants have spent nearly $8 billion acquiring systemic radiopharmaceutical platforms that deliver radioactive payloads through the bloodstream. These work well for metastatic cancers but have limitations
As reimbursement tightens and capital returns, clinically validated wound care assets are becoming scarce – and strategically valuable
Pancreatic cancer remains one of the deadliest diagnoses in medicine. While survival rates for many cancers have improved steadily over the past two decades, pancreatic cancer has lagged far behind. According to the Pancreatic Cancer Action Network, the five-year survival rate is just 13%, and the disease is projected
